TVTX (Travere Therapeutics) Cyclically Adjusted Revenue per Share: $4.36 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TVTX Travere Therapeutics Inc TVTX
61 GF Score
Price $65.71
GF Value $36.75
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Travere Therapeutics Cyclically Adjusted Revenue per Share?

Travere Therapeutics TVTX +1.96% 61 Cyclically Adjusted Revenue per Share is $4.36 as of Jun. 2026. GuruFocus rates TVTX with a GF Score™ of 61/100 and a GF Value™ of $36.75 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Travere Therapeutics's adjusted revenue per share for the three months ended in Jun. 2026 was $1.814. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $4.36 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Travere Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 8.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 2.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Travere Therapeutics was 4.00% per year. The lowest was 0.80% per year. And the median was 2.60% per year.

As of today (2026-08-22), Travere Therapeutics's current stock price is $65.705. Travere Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $4.36. Travere Therapeutics's Cyclically Adjusted PS Ratio of today is 15.07.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Travere Therapeutics was 15.08. The lowest was 1.41. And the median was 5.58.


Travere Therapeutics  (NAS:TVTX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Travere Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=65.705/4.36
=15.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Travere Therapeutics was 15.08. The lowest was 1.41. And the median was 5.58.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Travere Therapeutics Cyclically Adjusted Revenue per Share Related Terms


Travere Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Travere Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Travere Therapeutics Cyclically Adjusted Revenue per Share Chart

Travere Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.59 3.68 3.62 3.88 4.14

Travere Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.01 4.11 4.14 4.25 4.36

TVTX vs ORKA, DNTH, SRRK: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Travere Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Travere Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Travere Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Travere Therapeutics's Cyclically Adjusted PS Ratio falls into.


TVTX
61GF Score
Travere Therapeutics Inc TVTX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Travere Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Travere Therapeutics's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.814/333.9520*333.9520
=1.814

Current CPI (Jun. 2026) = 333.9520.

Travere Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.918 241.428 1.270
201612 0.869 241.432 1.202
201703 0.859 243.801 1.177
201706 0.994 244.955 1.355
201709 1.044 246.819 1.413
201712 1.050 246.524 1.422
201803 0.969 249.554 1.297
201806 1.032 251.989 1.368
201809 1.000 252.439 1.323
201812 1.060 251.233 1.409
201903 0.956 254.202 1.256
201906 1.066 256.143 1.390
201909 1.033 256.759 1.344
201912 1.085 256.974 1.410
202003 1.096 258.115 1.418
202006 1.082 257.797 1.402
202009 1.004 260.280 1.288
202012 0.994 260.474 1.274
202103 0.843 264.877 1.063
202106 0.902 271.696 1.109
202109 1.122 274.310 1.366
202112 -0.623 278.802 -0.746
202203 0.768 287.504 0.892
202206 0.851 296.311 0.959
202209 0.438 296.808 0.493
202212 0.457 296.797 0.514
202303 0.453 301.836 0.501
202306 0.424 305.109 0.464
202309 0.486 307.789 0.527
202312 0.589 306.746 0.641
202403 0.536 312.332 0.573
202406 0.698 314.175 0.742
202409 0.809 315.301 0.857
202412 0.900 315.605 0.952
202503 0.925 319.799 0.966
202506 1.287 322.561 1.332
202509 1.607 324.800 1.652
202512 1.436 324.054 1.480
202603 1.385 330.213 1.401
202606 1.814 333.952 1.814

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $4.36 mean?
Travere Therapeutics (TVTX) has a Cyclically Adjusted Revenue per Share of $4.36 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Travere Therapeutics and its competitors.
Is Travere Therapeutics' Cyclically Adjusted Revenue per Share too high?
Travere Therapeutics' current Cyclically Adjusted Revenue per Share is $4.36. Overall, Travere Therapeutics has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Travere Therapeutics' Cyclically Adjusted Revenue per Share compare to ORKA and DNTH?
Travere Therapeutics' Cyclically Adjusted Revenue per Share of $4.36 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Travere Therapeutics and its competitors. Travere Therapeutics's current Cyclically Adjusted Revenue per Share is $4.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Travere Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Travere Therapeutics (TVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $36.75, compared to a current price of $65.71 — trading 78.8% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $4.36. Travere Therapeutics' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Travere Therapeutics (TVTX), the current Cyclically Adjusted Revenue per Share is $4.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Travere Therapeutics (TVTX) Overvalued in 2026?

Based on GuruFocus' analysis, Travere Therapeutics stock appears to be overvalued. The current stock price of $65.71 is trading 78.8% above its estimated GF Value™ of $36.75. GuruFocus considers Travere Therapeutics to be Significantly Overvalued.

Key valuation signals for TVTX:

  • Cyclically Adjusted Revenue per Share: $4.36
  • GF Value™: $36.75 vs. price of $65.71 (78.8% above fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the TVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Travere Therapeutics Business Description

Address 3611 Valley Centre Drive, Suite 300, San Diego, CA, USA, 92130
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
61GF Score

Get the complete analysis for TVTX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$65.71
Price
$36.75
GF Value